The primary objective is to demonstrate the safety and effectiveness of the Axys EX rotational atherectomy system in subjects with peripheral arterial disease who have de novo or non-stented restenotic obstructive lesions in the peripheral vasculature of the lower limbs.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed
Primary Effectiveness
Change in percent stenosis in the treatment vessel. Percent stenosis is defined as native vessel diameter as measured at the narrowest point of the lesion divided by the estimated native vessel diameter at that location.
Time frame: During procedure
Primary Safety
Major Adverse Events (MAEs) at 30 Days post-procedure defined as freedom from clinically-driven target lesion revascularization (CD-TLR), major unplanned amputation of the treated limb, or all-cause mortality.
Time frame: 30-Days
Technical Success
Defined as the ability of the Axys EX device to successfully traverse/cross the entire intended length of the target lesion
Time frame: During Procedure
Procedural Success
Defined as ≤ 30% residual stenosis following use of the Axys EX device and adjunctive therapy as measured by angiography and determined by the angiographic core laboratory
Time frame: During Procedure
Amputation-Free Survival
Defined as freedom from a major, unplanned amputation of the target limb through the 12 month visit
Time frame: 12-Months
Major Adverse Events (MAEs)
Defined as freedom from clinically-driven target vessel revascularization (CD-TVR), major unplanned amputation of the treated limb, thrombosis at the target lesion site, or all-cause mortality
Time frame: 12-Months
Rate of Target Lesion Revascularization (TLR)
Any re-intervention at the target lesion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 6 and 12-Months
Rate of Target Vessel Revascularization (TVR)
Any re-intervention within the target vessel
Time frame: 6 and 12-Months
Provisional Stent Rate
Time frame: During Procedure
Flow Limiting Dissection
Target lesion flow limiting dissection (D or greater) rate after adjunctive therapy
Time frame: During Procedure
Primary Patency as determined by Duplex Ultrasound (DUS)
1. For subjects with a target lesion in the femoropopliteal region (above the knee \[ATK\]) through the level of popliteal segment P3 (below the knee popliteal artery from the center of the knee joint space to the origin of anterior tibial artery), primary patency is defined as freedom from core laboratory-assessed restenosis (DUS PSVR ≤2.4) and CD-TLR (adjudicated by a Clinical Events Committee) 2. For subjects with a target lesion below the level of popliteal segment P3 (below the knee \[BTK\]), primary patency is defined as freedom from core laboratory-assessed absence of target lesion occlusion (no flow) as assessed by DUS and CD-TLR (adjudicated by a Clinical Events Committee)
Time frame: 6 and 12-Months
Quality of Life Assessment
EQ-5D questionnaire
Time frame: 30-Days, 6 and 12-Months
Walking Distance
6-Minute Walking Test
Time frame: 30-Days, 6 and 12-Months
Walking Capacity
Walking Impairment Questionnaire (WIQ)
Time frame: 30-Days, 6 and 12-Months
Ankle/brachial index (ABI) or toe/brachial index (TBI)
Time frame: 30-Days, 6 and 12-Months
Rutherford clinical category (RCC)
Time frame: 30-Days, 6 and 12-Months
Distal Embolization in Target Limb
Clinically significant distal embolization in target limb within 30 days defined as distal embolization requiring treatment by mechanical or pharmacologic means (other than a vasodilator) (adjudicated by a Clinical Events Committee)
Time frame: 30-Days
Major Vessel Perforation
requiring surgical or endovascular repair within 30 days (adjudicated by a Clinical Events Committee) 6.
Time frame: 30-Days